Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2025)
Historic Liabilities and Shareholders Equity for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $10.1 million.
- Rani Therapeutics Holdings' Liabilities and Shareholders Equity fell 7671.34% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year decrease of 5581.35%. This contributed to the annual value of $36.6 million for FY2024, which is 3674.63% down from last year.
- Latest data reveals that Rani Therapeutics Holdings reported Liabilities and Shareholders Equity of $10.1 million as of Q3 2025, which was down 7671.34% from $16.9 million recorded in Q2 2025.
- Rani Therapeutics Holdings' Liabilities and Shareholders Equity's 5-year high stood at $137.0 million during Q3 2021, with a 5-year trough of $10.1 million in Q3 2025.
- In the last 5 years, Rani Therapeutics Holdings' Liabilities and Shareholders Equity had a median value of $73.9 million in 2021 and averaged $72.8 million.
- Per our database at Business Quant, Rani Therapeutics Holdings' Liabilities and Shareholders Equity soared by 5640.24% in 2021 and then plummeted by 7671.34% in 2025.
- Rani Therapeutics Holdings' Liabilities and Shareholders Equity (Quarter) stood at $124.2 million in 2021, then decreased by 13.03% to $108.0 million in 2022, then plummeted by 46.39% to $57.9 million in 2023, then crashed by 36.75% to $36.6 million in 2024, then plummeted by 72.32% to $10.1 million in 2025.
- Its Liabilities and Shareholders Equity was $10.1 million in Q3 2025, compared to $16.9 million in Q2 2025 and $24.1 million in Q1 2025.